Last reviewed · How we verify
NAI + Pembrolizumab
NAI is a cGAS-STING agonist that activates innate immune signaling, combined with pembrolizumab, a PD-1 checkpoint inhibitor, to enhance anti-tumor immune responses.
NAI is a cGAS-STING agonist that activates innate immune signaling, combined with pembrolizumab, a PD-1 checkpoint inhibitor, to enhance anti-tumor immune responses. Used for Advanced or metastatic solid tumors (Phase 3 evaluation), Melanoma and other checkpoint inhibitor-responsive cancers.
At a glance
| Generic name | NAI + Pembrolizumab |
|---|---|
| Sponsor | ImmunityBio, Inc. |
| Drug class | STING agonist + PD-1 inhibitor combination |
| Target | cGAS-STING pathway + PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
NAI stimulates the cGAS-STING pathway to promote interferon production and dendritic cell activation, priming innate immunity. Pembrolizumab blocks PD-1 on T cells to relieve immune checkpoint inhibition. Together, they aim to overcome tumor immunosuppression through both innate immune activation and adaptive T-cell checkpoint relief.
Approved indications
- Advanced or metastatic solid tumors (Phase 3 evaluation)
- Melanoma and other checkpoint inhibitor-responsive cancers
Common side effects
- Fatigue
- Immune-related adverse events (irAEs)
- Injection site reactions
- Fever
Key clinical trials
- Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer (PHASE3)
- Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NAI + Pembrolizumab CI brief — competitive landscape report
- NAI + Pembrolizumab updates RSS · CI watch RSS
- ImmunityBio, Inc. portfolio CI